FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039728769> ?p ?o ?g. }

• W2039728769 endingPage "254" @default.
• W2039728769 startingPage "248" @default.
• W2039728769 abstract "Abstract Following the first synthesis of tritiated α‐melanocyte‐stimulating hormone (α‐MSH, α‐melanotropin) in 1974 by Medzihradszky et al. , several α‐MSH analogs were designed containing between 2 and 12 tritium atoms, the latter of which displayed a specific radioactivity of 12.21 GBq/μmol (330 Ci/mmol). Similarly, radioiodinated α‐MSH analogs of high purity, full biological activity and a specific radioactivity of approximatly 140 GBq/μmol were obtained. Although tritiated and radioiodinated α‐MSH became indispensable tools as tracer molecules for numerous in vitro and in vivo studies, above all for receptor identification and characterization as well as for structure‐activity studies, they did not fulfill the criteria required for therapeutic in vivo targeting of metastatic melanoma. Therefore, we recently developed α‐MSH analogs containing the universal metal chelator 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid (DOTA) in different positions of the molecule. As DOTA can equally well incorporate diagnostic (e.g. 111 In, 67,68 Ga) and therapeutic (e.g. 90 Y, 67 Cu) radionuclides, DOTA‐MSH compounds may serve for both melanoma scintigraphy and therapy. The analog DOTA‐[βAla 3 , Nle 4 , Asp 5 , D ‐Phe 7 , Lys 10 ]‐α‐MSH 3–10 (DOTA‐MSH OCT ), which contains the metal chelator at its N‐terminal end, displayed good in vitro MC1R affinity (IC 50 9.21 n m ). In vivo , [ 111 In]DOTA‐MSH OCT exhibited a favorable biodistribution profile after injection in B16‐F1 tumor‐bearing mice. The radiopeptide was rapidly cleared from blood through the kidneys and, most importantly, accumulated preferentially in the melanoma lesions. Lung and liver melanoma metastases could be clearly imaged on tissue section autoradiographs 4 h after injection of [ 111 In]DOTA‐MSH OCT . A comparative study of [ 111 In]DOTA‐MSH OCT with [ 111 In]DOTA‐[Nle 4 , D ‐Phe 7 ]‐α‐MSH ([ 111 In]DOTA‐NDP‐MSH) demonstrated the superiority of the DOTA‐MSH OCT peptide, particularly with respect to the amount of radioactivity taken up by non‐malignant organs, including bone, the most radiosensitive tissue. These results demonstrate that [ 111 In]DOTA‐MSH OCT specifically targets melanoma metastases and represents a lead compound for the development of therapeutic DOTA‐MSH analogs. Copyright © 2003 John Wiley & Sons, Ltd." @default.
• W2039728769 created "2016-06-24" @default.
• W2039728769 creator A5018118044 @default.
• W2039728769 creator A5050032670 @default.
• W2039728769 date "2003-09-01" @default.
• W2039728769 modified "2023-10-15" @default.
• W2039728769 title "Radiolabeled ?-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium" @default.
• W2039728769 cites W1919811975 @default.
• W2039728769 cites W1940583266 @default.
• W2039728769 cites W1963994866 @default.
• W2039728769 cites W1966592733 @default.
• W2039728769 cites W1969310218 @default.
• W2039728769 cites W1969694287 @default.
• W2039728769 cites W1970716955 @default.
• W2039728769 cites W1973069842 @default.
• W2039728769 cites W1984111562 @default.
• W2039728769 cites W1995823770 @default.
• W2039728769 cites W1996018952 @default.
• W2039728769 cites W1997880280 @default.
• W2039728769 cites W2002507728 @default.
• W2039728769 cites W2019705877 @default.
• W2039728769 cites W2020367089 @default.
• W2039728769 cites W2022674969 @default.
• W2039728769 cites W2025697667 @default.
• W2039728769 cites W2041062319 @default.
• W2039728769 cites W2044357064 @default.
• W2039728769 cites W2046098060 @default.
• W2039728769 cites W2072485822 @default.
• W2039728769 cites W2074506416 @default.
• W2039728769 cites W2079846452 @default.
• W2039728769 cites W2086704099 @default.
• W2039728769 cites W2091939318 @default.
• W2039728769 cites W2099564842 @default.
• W2039728769 cites W2118953179 @default.
• W2039728769 cites W2141439220 @default.
• W2039728769 cites W2142277003 @default.
• W2039728769 cites W2158767109 @default.
• W2039728769 cites W2164855735 @default.
• W2039728769 cites W2167947678 @default.
• W2039728769 cites W2330471367 @default.
• W2039728769 cites W2411523631 @default.
• W2039728769 cites W4241090796 @default.
• W2039728769 cites W4296766361 @default.
• W2039728769 cites W1984186689 @default.
• W2039728769 doi "https://doi.org/10.1002/jmr.633" @default.
• W2039728769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14523936" @default.
• W2039728769 hasPublicationYear "2003" @default.
• W2039728769 type Work @default.
• W2039728769 sameAs 2039728769 @default.
• W2039728769 citedByCount "26" @default.
• W2039728769 countsByYear W20397287692012 @default.
• W2039728769 countsByYear W20397287692013 @default.
• W2039728769 countsByYear W20397287692016 @default.
• W2039728769 countsByYear W20397287692017 @default.
• W2039728769 countsByYear W20397287692019 @default.
• W2039728769 countsByYear W20397287692022 @default.
• W2039728769 countsByYear W20397287692023 @default.
• W2039728769 crossrefType "journal-article" @default.
• W2039728769 hasAuthorship W2039728769A5018118044 @default.
• W2039728769 hasAuthorship W2039728769A5050032670 @default.
• W2039728769 hasConcept C121332964 @default.
• W2039728769 hasConcept C126322002 @default.
• W2039728769 hasConcept C150903083 @default.
• W2039728769 hasConcept C170493617 @default.
• W2039728769 hasConcept C177322064 @default.
• W2039728769 hasConcept C178790620 @default.
• W2039728769 hasConcept C185544564 @default.
• W2039728769 hasConcept C185592680 @default.
• W2039728769 hasConcept C197404232 @default.
• W2039728769 hasConcept C202751555 @default.
• W2039728769 hasConcept C207001950 @default.
• W2039728769 hasConcept C2777658100 @default.
• W2039728769 hasConcept C2777807558 @default.
• W2039728769 hasConcept C2779931791 @default.
• W2039728769 hasConcept C2780989459 @default.
• W2039728769 hasConcept C2993559085 @default.
• W2039728769 hasConcept C502942594 @default.
• W2039728769 hasConcept C55493867 @default.
• W2039728769 hasConcept C62538594 @default.
• W2039728769 hasConcept C71924100 @default.
• W2039728769 hasConcept C86803240 @default.
• W2039728769 hasConcept C98274493 @default.
• W2039728769 hasConceptScore W2039728769C121332964 @default.
• W2039728769 hasConceptScore W2039728769C126322002 @default.
• W2039728769 hasConceptScore W2039728769C150903083 @default.
• W2039728769 hasConceptScore W2039728769C170493617 @default.
• W2039728769 hasConceptScore W2039728769C177322064 @default.
• W2039728769 hasConceptScore W2039728769C178790620 @default.
• W2039728769 hasConceptScore W2039728769C185544564 @default.
• W2039728769 hasConceptScore W2039728769C185592680 @default.
• W2039728769 hasConceptScore W2039728769C197404232 @default.
• W2039728769 hasConceptScore W2039728769C202751555 @default.
• W2039728769 hasConceptScore W2039728769C207001950 @default.
• W2039728769 hasConceptScore W2039728769C2777658100 @default.
• W2039728769 hasConceptScore W2039728769C2777807558 @default.
• W2039728769 hasConceptScore W2039728769C2779931791 @default.
• W2039728769 hasConceptScore W2039728769C2780989459 @default.
• W2039728769 hasConceptScore W2039728769C2993559085 @default.

• next